Humanigen Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Cameron Durrant

Geschäftsführender

US$1.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	58.2%
Amtszeit als Geschäftsführer	8.3yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.4yrs

Jüngste Management Updates

Recent updates

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Cameron Durrant im Vergleich zu den Einnahmen von Humanigen verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2023	n/a	n/a	-US$54m
Dec 31 2022	US$1m	US$640k	-US$71m
Sep 30 2022	n/a	n/a	-US$109m
Jun 30 2022	n/a	n/a	-US$152m
Mar 31 2022	n/a	n/a	-US$192m
Dec 31 2021	US$10m	US$640k	-US$237m
Sep 30 2021	n/a	n/a	-US$235m
Jun 30 2021	n/a	n/a	-US$199m
Mar 31 2021	n/a	n/a	-US$153m
Dec 31 2020	US$2m	US$600k	-US$90m
Sep 30 2020	n/a	n/a	-US$59m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	US$785k	US$600k	-US$10m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	US$4m	US$600k	-US$12m
Sep 30 2018	n/a	n/a	-US$13m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$22m
Dec 31 2017	US$790k	US$600k	-US$22m

Vergütung im Vergleich zum Markt: CameronDie Gesamtvergütung ($USD1.10M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD659.68K).

Entschädigung vs. Einkommen: CameronDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Cameron Durrant (64 yo)

8.3yrs

Amtszeit

US$1,099,058

Vergütung

Dr. Cameron Durrant, MD, MBA, DRCOG, DIPCH, MRCGP, FLSW, has been Chairman of Humanigen, Inc. since January 2016. Dr. Durrant has been Chief Executive Officer at Humanigen, Inc. since March 2016 and has be...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Cameron Durrant	Chairman	8.4yrs	US$1.10m	keine Daten
Dale Chappell	Chief Scientific Officer & Director	3.3yrs	US$661.96k	0% $ 0
Rainer Boehm	Independent Director	6.3yrs	US$81.20k	0.071% $ 0.08
Ronald Barliant	Independent Director	8.4yrs	US$61.60k	0.075% $ 0.09

7.4yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: HGEN.QDie Vorstandsmitglieder gelten als erfahren (7.3 Jahre durchschnittliche Amtszeit).

Humanigen Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc. Announces Board Changes

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022

Humanigen, Inc., Annual General Meeting, Jun 09, 2022

Chairman & CEO recently bought US$94k worth of stock

Recent updates

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Humanigen, Inc. Announces Board Changes

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.035 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.75

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Humanigen Receives Non-Compliance Letter from Nasdaq

Bernstein Liebhard LLP Announces Class Action Lawsuit Against Humanigen, Inc

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022

Pomerantz LLP Announces the Filing of a Class Action Against Humanigen, Inc. and Certain of its Officers

Consensus revenue estimates increase by 34%

First half 2022 earnings released

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Price target decreased to US$8.70

Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

Humanigen plunges 57% as trial for COVID-19 therapy fails

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Consensus revenue estimates increase by 19%

Humanigen, Inc., Annual General Meeting, Jun 09, 2022

Chairman & CEO recently bought US$94k worth of stock

Forecast to breakeven in 2023

Consensus revenue estimates increase by 12%

Forecast to breakeven in 2023

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Humanigen, Inc. Announces Target Enrollment in Phase 2/3 Activ-5/Bet-B Trial of Lenzilumab for the Treatment of Covid-19 Has Been Achieved

Humanigen, Inc. Announces A Manuscript Detailing the Results of an Analysis of CRP Levels from the Live-Air Phase 3 Study

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

FDA Declines Humanigen’s Emergency Use Authorization Request for Lenzilumab in Hospitalized COVID-19 Patients

Price target decreased to US$28.33

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Chairman & CEO recently sold US$1.7m worth of stock

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Humanigen Submits Application to FDA for Emergency Use Authorization for lenzilumab in Covid-19

Humanigen submits lenzilumab COVID-19 EUA application to FDA

Eversana Advances Commercialization Readiness as Humanigen Announces Publication of Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Newly Hospitalized Covid-19 Patients

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Price target increased to US$32.14

Humanigen, Inc., Annual General Meeting, Jun 17, 2021

Humanigen, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Earnings beat expectations

Chief Accounting & Administrative Officer, Corporate Secretary and Treasurer has left the company

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

New 90-day high: US$23.83

Humanigen, Inc. Announces Executive Changes

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

Humanigen, Inc. Completes Enrollment in Phase 3 Study of Lenzilumab

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational Covid-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

Humanigen, Inc Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19

Humanigen, Inc. and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Humanigen, Inc. Announces Retirement of Robert G. Savage from the Board of Directors

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme